Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI109104

Neutralization of Glucagon by Antiserum as a Tool in Glucagon Physiology: LACK OF DEPRESSION OF BASAL BLOOD GLUCOSE AFTER ANTISERUM TREATMENT IN RATS

J. J. Holst, H. Galbo, and E. A. Richter

Department of Clinical Chemistry, Bispebjerg Hospital, Copenhagen, Denmark

Institute of Medical Physiology B, University of Copenhagen, Copenhagen, Denmark

Find articles by Holst, J. in: JCI | PubMed | Google Scholar

Department of Clinical Chemistry, Bispebjerg Hospital, Copenhagen, Denmark

Institute of Medical Physiology B, University of Copenhagen, Copenhagen, Denmark

Find articles by Galbo, H. in: JCI | PubMed | Google Scholar

Department of Clinical Chemistry, Bispebjerg Hospital, Copenhagen, Denmark

Institute of Medical Physiology B, University of Copenhagen, Copenhagen, Denmark

Find articles by Richter, E. in: JCI | PubMed | Google Scholar

Published July 1, 1978 - More info

Published in Volume 62, Issue 1 on July 1, 1978
J Clin Invest. 1978;62(1):182–190. https://doi.org/10.1172/JCI109104.
© 1978 The American Society for Clinical Investigation
Published July 1, 1978 - Version history
View PDF
Abstract

The method of producing experimental glucagon deficiency by administration of glucagon antiserum was evaluated in rats. A pool of antisera was prepared, the affinity of which exceeded that of the glucagon receptors of liver cell membranes, whereas the binding capacity of the volume used amounted to more than one-third of the total glucagon content in the rat pancreas. That rapid, extensive, and lasting neutralization of glucagon had taken place after antiserum treatment was indicated by the following findings: When examined more than 1 h after the injection and after 60 min of exercise-stimulated glucagon production, all rats had excess free antibodies in plasma. The concentration of free glucagon was lowered to one-third of the concentration in control rats; at 37°C plasma samples could bind 25% of additional 300 pmol/liter of glucagon in 10 s, and 69% in 120 s; the glycemic response to exogenous glucagon was abolished. Antiserum treatment, however, had no effect on blood glucose in rats fasted for 3 and 10 h, in chemically sympathectomized and adrenomedullectomized rats, and in 48-h-fasted, acutely adrenalectomized rats. The antiserum was found to contain 460 nmol/liter of antibody-bound glucagon, originating in the rabbit in which the antiserum was raised. However, antibody preparations from which the bound glucagon had been effectively removed were equally ineffective in lowering the basal blood glucose in rats, although in three-fourths of the rats the concentration of free glucagon was lowered beyond detection limit.

The data indicate that the absolute concentration of glucagon in plasma is of minor importance for the maintenance of basal blood glucose in the rat.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 182
page 182
icon of scanned page 183
page 183
icon of scanned page 184
page 184
icon of scanned page 185
page 185
icon of scanned page 186
page 186
icon of scanned page 187
page 187
icon of scanned page 188
page 188
icon of scanned page 189
page 189
icon of scanned page 190
page 190
Version history
  • Version 1 (July 1, 1978): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts